A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

Oncoimmunology · 2026 · PMC12934184 · PMID 41732954

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the difference did not reach statistical significance, patients with a high BTS demonstrated a trend toward poorer survival outcomes in this study (S_ Figure 2C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.